Beckmann M W, Juhasz-Böss I, Denschlag D, Gaß P, Dimpfl T, Harter P, Mallmann P, Renner S P, Rimbach S, Runnebaum I, Untch M, Brucker S Y, Wallwiener D
Universitätsklinikum Erlangen-Nürnberg, Frauenklinik, Erlangen.
Universitätsklinikum des Saarlandes, Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Homburg.
Geburtshilfe Frauenheilkd. 2015 Feb;75(2):148-164. doi: 10.1055/s-0035-1545684.
The appropriate surgical technique to treat patients with uterine fibroids is still a matter of debate as is the potential risk of incorrect treatment if histological examination detects a uterine sarcoma instead of uterine fibroids. The published epidemiology for uterine sarcoma is set against the incidence of accidental findings during surgery for uterine fibroids. International comments on this topic are discussed and are incorporated into the assessment by the German Society for Gynecology and Obstetrics (DGGG). The ICD-O-3 version of 2003 was used for the anatomical and topographical coding of uterine sarcomas, and the "Operations- und Prozedurenschlüssel" (OPS) 2014, the German standard for process codes and interventions, was used to determine surgical extirpation methods. Categorical qualifiers were defined to analyze the data provided by the Robert Koch Institute (RKI), the German Federal Bureau of Statistics (DESTATIS; Hospital and Causes of Death Statistics), the population-based Cancer Register of Bavaria. A systematic search was done of the MEDLINE database and the Cochrane collaboration, covering the period from 1966 until November 2014. The incidence of uterine sarcoma and uterine fibroids in uterine surgery was compared to the literature and with the different registries. The incidence of uterine sarcoma in 2010, standardized for age, was 1.53 for Bavaria, or 1.30 for every 100 000 women, respectively, averaged for the years 2002-2011, and 1.30 for every 100 000 women in Germany. The mean incidence collated from various surveys was 2.02 for every 100 000 women (0.35-7.02; standard deviation 2.01). The numbers of inpatient surgical procedures such as myoma enucleation, morcellation, hysterectomy or cervical stump removal to treat the indication "uterine myoma" have steadily declined in Germany across all age groups (an absolute decrease of 17 % in 2012 compared to 2007). There has been a shift in the preferred method of surgical access from an abdominal/vaginal approach to endoscopic or endoscopically assisted procedures to treat uterine fibroids, with the use of morcellation increasing by almost 11 000 coded procedures in 2012. Based on international statements (AAGL, ACOG, ESGE, FDA, SGO) on the risk of uterine sarcoma as an coincidental finding during uterine fibroid surgery and the associated risk of a deterioration of prognosis (in the case of morcellation procedures), this overview presents the opinion of the DGGG in the form of four Statements, five Recommendation and four Demands.
治疗子宫肌瘤患者的合适手术技术仍存在争议,同样存在的争议是,如果组织学检查发现是子宫肉瘤而非子宫肌瘤,那么不正确治疗的潜在风险也备受关注。已公布的子宫肉瘤流行病学数据是与子宫肌瘤手术中意外发现的发生率相对照的。本文讨论了关于这一主题的国际观点,并纳入了德国妇产科学会(DGGG)的评估中。2003年版的ICD - O - 3用于子宫肉瘤的解剖学和地形学编码,2014年的“手术与操作编码标准”(OPS)作为德国手术编码和干预措施的标准,用于确定手术切除方法。定义了分类限定词,以分析由罗伯特·科赫研究所(RKI)、德国联邦统计局(DESTATIS;医院与死因统计)以及巴伐利亚州基于人群的癌症登记处提供的数据。对MEDLINE数据库和Cochrane协作网进行了系统检索,涵盖1966年至2014年11月期间。将子宫手术中子宫肉瘤和子宫肌瘤的发生率与文献以及不同登记处的数据进行了比较。2010年巴伐利亚州子宫肉瘤的年龄标准化发病率为1.53,即每10万名女性中有1.30例,这是2002 - 2011年的平均数据,德国每10万名女性中的发病率为1.30。各种调查汇总的平均发病率为每10万名女性中有2.02例(0.35 - 7.02;标准差2.01)。在德国,所有年龄组中用于治疗“子宫肌瘤指征”的住院手术程序数量,如肌瘤剜除术、粉碎术、子宫切除术或宫颈残端切除术等均呈稳步下降趋势(与2007年相比,2012年绝对下降了17%)。治疗子宫肌瘤的手术入路首选方法已从腹部/阴道途径转向内镜或内镜辅助手术,2012年粉碎术的编码程序增加了近11000例。基于国际组织(AAGL、ACOG、ESGE、FDA、SGO)关于子宫肉瘤在子宫肌瘤手术中作为意外发现的风险以及相关预后恶化风险(在粉碎术的情况下)的声明,本综述以四项声明、五项建议和四项要求的形式呈现了DGGG的观点。